----Hematology Diseases

A. Introduction of the Team

Within the current 154 medical and technical staff, there are 30 active professors and associate professors, 15 doctoral supervisors and 14 master’s supervisors, 1 Yangtze River Scholar and Distinguished Professor of the Ministry of Education, 2 recipients of National Science Fund for Distinguished Young Scholars, 1 recipient of the National New-century Talents project, 3 recipients of outstanding doctoral thesis awards of Hubei Province. 50% of our staff have studied abroad, and 70% of the physicians have PhD degrees.  

Team Leader: Prof. Dr. HU Yu, Doctor of Medicine, professor, chief physician, doctoral supervisor, Director of department of hematology and institute of hematology, President of Union Hospital, Tongji Medical School, Huazhong University of Science and Technology.

Dr. Hu has undertaken 21 national and provincial research projects. He is also the leader of the following projects: one of Major Projects for "Significant New Drugs Development" of the Ministry of Science and Technology, subsection of “973 project”, one of the National Outstanding Youth Funding, three of the Key Clinical Projects of the Ministry of Health, one of Innovative Research Team of the Ministry of Education, one of International Cooperation and Exchange programs and five general programs of the National Natural Science Foundation of China. Dr. Hu has been awarded as the New Century talents by State Personnel Board and the Ministry of Education in 2007, and received the National Science Fund for Distinguished Young Scholars in 2009, and rewarded as “Yangtze river scholars” in 2009, Young experts with outstanding contributions by the Ministry of Health in 2012, Leading talent in the national press and publishing industry in 2013.

Team members

Dr. XIA Linghui, Professor, chief physician, doctoral supervisor. Member of Chinese committee of donor bank of hematopoietic stem cells, member of hematology section of Chinese Geriatrics Society, standing committee member of Hematology professional committees of Cross-strait medical and Health Association, member and secretory of Hubei Hematology Association, vice chairman of hematology section of Chinese Interactive Medicine Association, vice chairman of Hubei Biomedical immunology association committee, member of Hubei Transplantation Association.

Dr. GUO Tao, Chief physician, doctoral supervisor, member of Chinese College of Hematology Physicians, member of thrombosis and hemostasis section of Chinese Medical Association, Chairman of Wuhan Hematology Association

Dr. SUN Chunyan, Chief physician, doctoral supervisor, youth committee member of hematology section of Chinese Medical Association, Member of hematological pathology workgroup of Hematologic Malignancies of Chinese Anti-Cancer Association, Standing committee member of Lymphoma section of Hubei Anti-Cancer Association, Member of Wuhan Hematology Association. Dr. Sun specializes in the pathogenesis and targeted treatment of malignant tumors, including myeloma, lymphoma, leukemia and other hematologic malignant diseases, as well as the diagnosis and treatment of myelodysplastic syndromes, aplastic anemia. She has received two funding from National Natural Science Foundation, one from Research Fund Project of Hubei Health Department, and has over 40 publications in national and international journals. She was awarded the first prize of science and technology progress in Hubei Province in 2007 and 2012 respectively.

Dr. WANG Huafang, doctoral supervisor, office director of the hematology institute of Union Hospital, Member of transplantation section of Wuhan Medical Association, Registered physician of Hubei Diagnosis and Treatment center for Hemophilia of World Federation of Hemophilia, Editor of Thrombosis Haemostasis, English proofreader of Clinical hematology.

Dr. MEI Heng, deputy chief physician, Master’s supervisor, Member of hematology section of Chinese Geriatrics Society, Member of biotherapy section of Chinese Research Hospital Association, Standing committee member of Experimental Hematology section of Chinese Association of Pathophysiology, Youth committee member of Internal Medicine section of Chinese Medical Association Dr. Mei specialized in clinical diagnosis and treatment of hematological diseases, especially in the treatment of malignant hematologic diseases and the diagnosis and treatment of complex and complicated blood coagulation disease. His research focuses on CAR-T therapy for hematological malignancies and the innovative diagnosis and treatment of DIC. Dr. Mei has spent 2 years for advanced studies in one of the hospitals in the US, directed 6 of national and provincial and ministerial research programs, published more than 20 clinical research papers, undertook 4 national and international clinical research programs. He has received 1 patent, first prize of scientific and technological progress of the Ministry of Education in 2015 and first prize of Hubei science and technology achievement promotion.

Dr. SHI Wei, deputy chief physician; specializes in hematological malignancies, complex haemorrhage and coagulation disorders and hematopoietic stem cell transplantation, published 20+ SCI papers, 5 of which have over-5 impact factor.

Dr. TANG Liang, medical doctor, attending physician; published 19 SCI papers as first or correspondence author.

B. Research Interest

By taking advantage of modern diagnosis and treatment technologies, we have enhanced the accuracy of diagnosis and classification of hematologic malignancies and other diseases, as well as the competence of blood diseases diagnosis and treatment in Hubei province and even the entire southwest and central China. We specialize in hematopoietic stem cell transplantation, thrombosis and hemostasis, multiple myeloma, leukemia, immunotherapy (CAR-T). We also have reached international level of excellence in the treatment of blood diseases including leukemia, lymphoma, multiple myeloma, and blood coagulation diseases.

C. Research Achievements

In the past five years, our department has stayed at the 5th or 6th in the three major rankings in China. There are 44 National Natural Science Foundation projects from 2011 to 2017, as well as over 60 projects including special project of “Significant New Drugs Development" of the Ministry of Science and Technology, Innovative Team of the Ministry of Education, National Science Fund for Distinguished Young Scholars, subsection of national “973” project, National Key Scientific and Technological project, with total funding of almost 50 million. We also have over 10 evaluation projects, most of which are at top level domestically or abroad. Within 236 SCI publications, 54 have impact factor over 5, and 3 over 10. As the first applicant, Dr. Hu have applied for 3 patents, one of which got certified. The provincial and ministerial awards are lists as follows:

D. Advantages and Resources

In Union Hospital, this team is in charge of 6 labs with a total area of over 800 square meters. The thrombosis and hemostasis clinical research center of Hubei Province has research and technical staff and all facilities, including ultra-low temperature refrigerator, low-temperature centrifuge, Gel Imager, real-time quantitative PCR, protein electrophoresis device, cell culture equipment, confocal microscope, Flow cytometry, Macromolecular Interaction Instrument (SPR) and others. Annually, 20 graduate students could get training here. There is a GMP-certified cell culture lab in the Hubei clinical research center of cell therapy of malignancies. We have established a whole set of CAR-T Immunotherapy, and initiated clinical trials. So far, over 30 cases of refractory-relapsed leukemia have been treated successfully. The molecular diagnosis platform of hematologic diseases has been authenticated by international standardization organization (ISO) led by Peking University. With annual tests of 5000 cases, it has become the gold standard for gene diagnosis in hematology department of major hospitals in southwest China. Among them, the diagnosis platform of thrombophilia, the molecular diagnosis of 9,978 patients was performed in 26 hospitals nationwide, and the etiology of thrombosis was identified for 2,115 patients. The annual outpatient service was more than 80,000, the number of inpatients was more than 7000, the efficiency of diagnosis and treatment was over 95%, and patient satisfaction rate reached 98%.

Team Contact: MEI Heng, mayheng@126.com